JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer

  • 0Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tays Cancer Center, Tampere University, Tampere, Finland.
Cancer Research +

|

December 9, 2024

|

December 9, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

Researchers analyzed plasma cell-free DNA (cfDNA) to understand prostate cancer phenotypes. This noninvasive method reveals tumor biology and may help monitor treatment resistance.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genomics

Background

  • Prostate cancer phenotypes influence disease presentation and treatment resistance.
  • Accessing metastatic tissue for chromatin biology studies is limited, often relying on non-representative preclinical models.
  • Plasma cell-free DNA (cfDNA) offers a potential noninvasive source for studying prostate cancer epigenomics.

Purpose Of The Study

  • To analyze histone modifications (H3K4me2) in cfDNA from metastatic prostate cancer patients to capture diverse phenotypes.
  • To correlate cfDNA epigenomic features with clinicogenomic data and treatment response.
  • To establish plasma cfDNA chromatin profiling as a tool for biomarker discovery and biological insights.

Main Methods

  • Chromatin immunoprecipitation sequencing (ChIP-seq) of H3K4me2 from plasma cfDNA.
  • Analysis of cfDNA epigenomic data in relation to ctDNA fraction, metastatic patterns, and clinical presentation.
  • Correlation of chromatin hallmarks with clinicogenomic features like PSA levels, histopathology, and genetic deletions (RB1).

Main Results

  • H3K4me2 density in cfDNA correlated with ctDNA fraction, reflecting prostate cancer biology.
  • Epigenomic profiles segregated tumors based on metastatic site (bone vs. liver), clinical features, and androgen receptor activity.
  • Observed lineage switching post-therapy in some patients, suggesting potential for resistance monitoring.
  • Identified epigenomic footprints of normal tissue destruction in cfDNA.

Conclusions

  • Plasma cfDNA chromatin profiling is a viable noninvasive method for dissecting lethal prostate cancer phenotypes.
  • This approach overcomes limitations of tissue accessibility and reliance on model systems.
  • Plasma cfDNA epigenomics serves as a valuable source for biomarker discovery and understanding tumor adaptability.